bal pharma reported a standalone net profit of ₹370.02 lakh for the quarter ended March 31, 2026, down from ₹560.69 lakh in the corresponding period of FY25. Revenue from operations increased modestly to ₹8,391.76 lakh from ₹8,178.36 lakh year-on-year. The decline in profitability occurred despite higher revenue, driven by increased employee benefits and other expenses. For the full financial year, standalone net profit stood at ₹675.12 lakh, compared to ₹779.95 lakh in FY25.

The Board of Directors recommended a dividend of Re.1 per equity share of ₹10 face value, representing a 10% payout, subject to shareholder approval at the Annual General Meeting. Statutory auditors SSJNB & Co issued an unmodified opinion on the audited standalone and consolidated financial results. The company also refiled its XBRL financial results to align with PDF figures, citing technical validation issues in the initial submission as the cause for earlier discrepancies.

Financial Performance

Standalone revenue from operations grew marginally in Q4FY26, while total income reached ₹8,369.95 lakh against ₹8,277.46 lakh in Q4FY25. However, operating expenses rose significantly. Employee benefits expenses increased to ₹1,791.82 lakh from ₹1,534.90 lakh, and other expenses climbed to ₹1,699.00 lakh from ₹1,465.88 lakh. Finance costs remained relatively stable at ₹405.26 lakh. Consequently, profit before tax was ₹331.41 lakh, lower than the ₹281.38 lakh reported in the prior year quarter, but net profit fell more sharply due to tax adjustments.

Consolidated figures showed similar trends. Consolidated net profit for the quarter attributable to equity holders was ₹359.35 lakh, down from ₹543.31 lakh in Q4FY25. Consolidated revenue from operations was ₹8,407.57 lakh, up from ₹8,187.62 lakh. For the full year, consolidated net profit attributable to equity holders was ₹628.38 lakh, compared to ₹721.53 lakh in FY25.

Balance Sheet and Cash Flow

As of March 31, 2026, standalone total assets stood at ₹39,105.51 lakh, an increase from ₹35,056.39 lakh in the previous year. Non-current assets rose to ₹11,541.96 lakh, driven by additions in property, plant, and equipment. Current liabilities increased to ₹24,330.15 lakh from ₹21,345.82 lakh, primarily due to higher borrowings and trade payables. Standalone cash and cash equivalents were ₹219.49 lakh, up from ₹163.95 lakh.

Operating cash flow generated ₹3,083.38 lakh for the year, compared to ₹2,031.43 lakh in FY25. Investing activities consumed ₹2,069.38 lakh, mainly due to capital expenditures on property, plant, and equipment. Financing activities resulted in a net outflow of ₹958.47 lakh, reflecting interest payments and dividend distributions.

Corporate Developments

During the Board meeting held on May 27, 2026, the company appointed Shreepada M L as Company Secretary and Compliance Officer, replacing Abdul Basith who resigned effective May 11, 2026. Shreepada brings over seven years of experience across various industries. The Board also approved the grant of 500,000 stock options to employees under the Bal Pharma Limited Employee Stock Option Plan-2025 and authorized a preferential issue of 1,000,000 warrants to promoters, subject to shareholder approval via postal ballot.

Internal auditor Murugesh & Co and cost auditor G.N.V & Associates were appointed for FY26. The company operates in a single reportable segment: Pharmaceuticals.

Bal Pharma Limited has revised the pricing and payment terms for its proposed preferential issue of convertible warrants, raising the issue price to ₹84 per warrant from an earlier ₹81. The adjustment increases the total potential capital raise to ₹8.4 crore, which is designated to fund a greenfield Active Pharmaceutical Ingredients (API) manufacturing facility in Yadgiri, Karnataka. This strategic move aims to strengthen the company’s manufacturing capabilities and support long-term growth in the pharmaceutical sector, with shareholders currently voting on the matter via remote e-voting.

The corrigendum to the postal ballot notice, dated July 23, 2026, was issued following clarifications sought by the National Stock Exchange of India Limited (NSE) and BSE Limited under the Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2018 (SEBI ICDR Regulations). The remote e-voting process, which commenced on July 10, 2026, remains open until August 8, 2026, at 5:00 P.M. IST. Shareholders who have already voted may modify their votes by contacting the scrutinizer before the deadline.

Revised Pricing and Valuation

The new issue price of ₹84 per warrant includes a premium of ₹74 per warrant, aligning with regulatory requirements that mandate a minimum price based on valuation reports and trading volumes. An independent registered valuer, Mr. CA S. Bhaskar, determined the fair value using multiple approaches, with the market approach yielding the highest value of ₹83.869 per equity share. This figure also matched the 90-day volume-weighted average price on the NSE, establishing the regulatory floor price. The company opted for a slightly higher price of ₹84 to ensure compliance and reflect fair value.

Payment Terms and Conversion Structure

Consequent to the price revision, the payment structure for the 10,00,000 warrants has been adjusted. Warrant holders must pay 25% of the consideration, amounting to ₹21 per warrant, on the date of allotment. The remaining 75%, or ₹63 per warrant, is due before the conversion of warrants into equity shares. Each warrant is convertible into one equity share with a face value of ₹10. The conversion window extends up to 18 months from the date of allotment. Failure to convert within this period will result in the forfeiture of paid amounts and lapse of rights.

Project Details and Utilization of Proceeds

The proceeds from the warrant issue are exclusively allocated to the greenfield API manufacturing project at Yadgiri, Karnataka. Bal Pharma has already acquired approximately 5 acres of land through the Karnataka Industrial Areas Development Board (KIADB) and obtained prior environmental clearance from the Ministry of Environment, Forest and Climate Change (MoEF&CC). The total project cost is estimated at approximately ₹300 crore, with the ₹8.4 crore from this issue covering initial capital expenditures such as construction, machinery installation, and infrastructure development. The company intends to utilize the funds by December 31, 2027, pending phased receipt of proceeds upon warrant conversions.

Impact on Shareholding Pattern

Upon full conversion of the 10,00,000 warrants and 10,00,000 employee stock options, the promoter holding of Mr. Shailesh Siroya will increase from 17.24% to 20.89% of the total equity. The overall promoter group holding will remain stable at approximately 50.76% on a fully diluted basis. The company confirmed that there will be no change in management or control, and the transaction complies with SEBI’s Substantial Acquisition of Shares and Takeovers (SAST) Regulations.